Journal of Diagnostics Concepts & Practice >

2022 , Vol. 21 >Issue 04: 490 - 496

DOI: https://doi.org/10.16150/j.1671-2870.2022.04.012

Original articles

Pan-cancer analysis of plasmacytoma variant translocation 1 and MYC gene expression pattern and survival prediction

Expand
  • 1. Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
    2. Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received date: 2022-06-15

  Online published: 2022-11-07

Fold

Abstract

Objective: To explore the expression levels and survival prediction of plasmacytoma variant translocation 1 (PVT1) and MYC gene in pan-cancer. Methods: The clinic data and RNA-seq data from 31 types of cancer tissues totaling 10 016 cases were retrieved from The Cancer Genome Atlas (TCGA) database, among which 23 types of cancer with adjacent tissues as normal controls. Student t-tests were used to analyze the significant differences of PVT1 or MYC gene expression levels between cancer tissues and corresponding normal controls. Spearman correlation was used to analyze the expression correlation between PVT1 and MYC in 31 types of cancer. The relationship between PVT1 or MYC expression and overall survival of 31 types of cancer patients was depicted by the Kaplan-Meier curve and Cox proportional hazards model. Results: =PVT1 expression was highly expressed in 19 types of cancer(P<0.05) and lowly expressed in 2 types of cancer (P<0.05). MYC expression was significantly upregulated in 7 types of cancer (P<0.05) and downregulated in 6 types of cancer (P<0.05). Expression correlation analysis presented that PVT1 expression was positively correlated with MYC in about 87% (27/31) types of cancer (Rho>0, P<0.01). Finally, survival analysis showed that relatively high expression of PVT1 was significantly associated with shorter overall survival in bladder urothelial carcinoma, breast invasive carcinoma, adrenocortical carcinoma, renal clear cell carcinoma, renal papillary cell carcinoma, lower grade glioma, prostate adenocarcinoma, testicular germ cell tumors and uveal melanoma (log-rank P<0.05). The relatively high expression group of MYC was significantly correlated with shorter overall survival in adrenocortical carcinoma, bladder urothelial carcinoma, cervical squamous cell carcinoma, head and neck squamous cell carcinoma, renal papillary cell carcinoma, ovarian serous cystadenocarcinoma, pancreatic adenocarcinoma and sarcoma (log-rank P<0.05), while was associated with long-time survival in lower grade glioma and rectum adenocarcinoma (log-rank P<0.05). Conclusions: The increased expression of PVT1 in pan-cancer is more prevalent than that of MYC. The positive correlation between PVT1 and MYC indicates a potential regulatory relationship in cancers. Furthermore, the relatively high expression of PVT1 has a poor effect on the overall survival of patients in 9 types of cancer, while the expression level of MYC presents different effects on the overall survival of patients in various cancers.

Key words： Plasmacytoma variant translocation 1 gene; MYC gene; Tumor; Survival time

Cite this article

MA Xuefei, WANG Xuefeng, WANG Kankan . Pan-cancer analysis of plasmacytoma variant translocation 1 and MYC gene expression pattern and survival prediction[J]. Journal of Diagnostics Concepts & Practice, 2022 , 21(04) : 490 -496 . DOI: 10.16150/j.1671-2870.2022.04.012

References

[1] Jiang N, Zhang X, Gu X, et al. Progress in understanding the role of lncRNA in programmed cell death[J]. Cell Death Discov, 2021, 7(1):30.
[2] Wang W, Min L, Qiu X, et al. Biological function of long non-coding RNA (LncRNA) xist[J]. Front Cell Dev Biol, 2021, 9:645647.
[3] McCabe EM, Rasmussen TP. lncRNA involvement in cancer stem cell function and epithelial-mesenchymal transitions[J]. Semin Cancer Biol, 2021, 75:38-48.
[4] Jin K, Wang S, Zhang Y, et al. Long non-coding RNA PVT1 interacts with MYC and its downstream molecules to synergistically promote tumorigenesis[J]. Cell Mol Life Sci, 2019, 76(21):4275-4289.
[5] Tseng YY, Moriarity BS, Gong W, et al. PVT1 dependence in cancer with MYC copy-number increase[J]. Nature, 2014, 512(7512):82-86.
[6] Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses[J]. Neoplasia, 2017, 19(8):649-658.
[7] Li B, Severson E, Pignon JC, et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy[J]. Genome Biol, 2016, 17(1):174.
[8] Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells[J]. Cancer Res, 2017, 77(21):e108-e110.
[9] Li T, Fu J, Zeng Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells[J]. Nucleic Acids Res, 2020, 48(W1):W509-W514.
[10] Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses[J]. Nucleic Acids Res, 2017, 45(W1):W98-W102.
[11] Cancer Genome Atlas Research Network, Weinstein JN, Collisson EA, et al. The cancer genome atlas pan-cancer analysis project[J]. Nat Genet, 2013, 45(10):1113-1120.
[12] Espinoza I, Agarwal S, Reddy A, et al. Expression of trefoil factor 3 is decreased in colorectal cancer[J]. Oncol Rep, 2021, 45(1):254-264.
[13] Huang S, Li D, Zhuang L, et al. Identification of Arp2/3 complex subunits as prognostic biomarkers for hepatocellular carcinoma[J]. Front Mol Biosci, 2021, 8:690151.
[14] Luan W, Ding Y, Ma S, et al. Long noncoding RNA LIN 00518 acts as a competing endogenous RNA to promote the metastasis of malignant melanoma via miR-204-5p/AP1S2 axis[J]. Cell Death Dis, 2019, 10(11):855.
[15] Yang YR, Zang SZ, Zhong CL, et al. Increased expression of the lncRNA PVT1 promotes tumorigenesis in non-small cell lung cancer[J]. Int J Clin Exp Pathol, 2014, 7(10):6929-6935.
[16] Guo J, Hao C, Wang C, et al. Long noncoding RNA PVT1 modulates hepatocellular carcinoma cell proliferation and apoptosis by recruiting EZH2[J]. Cancer Cell Int, 2018, 18:98.
[17] Tang J, Li Y, Sang Y, et al. LncRNA PVT1 regulates triple-negative breast cancer through KLF5/beta-catenin signaling[J]. Oncogene, 2018, 37(34):4723-4734.
[18] Zhao J, Du P, Cui P, et al. LncRNA PVT1 promotes angiogenesis via activating the STAT3/VEGFA axis in gastric cancer[J]. Oncogene, 2018, 37(30):4094-4109.
[19] Fang J, Huang J. Clinical significance of the expression of long non-coding RNA PVT1 in glioma[J]. Cancer Biomark, 2019, 24(4):509-513.
[20] Wu H, Wei M, Jiang X, et al. lncRNA PVT1 Promotes tumorigenesis of colorectal cancer by stabilizing miR-16-5p and interacting with the VEGFA/VEGFR1/AKT Axis[J]. Mol Ther Nucleic Acids, 2020, 20:438-450.
[21] Zhou C, Yi C, Yi Y, et al. LncRNA PVT1 promotes gemcitabine resistance of pancreatic cancer via activating Wnt/β-catenin and autophagy pathway through modula-ting the miR-619-5p/Pygo2 and miR-619-5p/ATG14 axes[J]. Mol Cancer, 2020, 19(1):118.
[22] Schaub FX, Dhankani V, Berger AC, et al. Pan-cancer alterations of the MYC oncogene and its proximal network across the cancer genome atlas[J]. Cell Syst, 2018, 6(3):282-300.
[23] Duffy MJ, O'Grady S, Tang M, et al. MYC as a target for cancer treatment[J]. Cancer Treat Rev, 2021, 94:102154.
[24] Shigeyasu K, Toden S, Ozawa T, et al. The PVT1 lncRNA is a novel epigenetic enhancer of MYC, and a promising risk-stratification biomarker in colorectal cancer[J]. Mol Cancer, 2020, 19(1):155.
[25] Zhang MX, Zhang LZ, Fu LM, et al. Positive feedback regulation of lncRNA PVT1 and HIF2α contributes to clear cell renal cell carcinoma tumorigenesis and metastasis[J]. Oncogene, 2021, 40(37):5639-5650.
Options
Outlines

/

〈 〉